• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在德国一个大型肝细胞癌患者队列中对MESH、HKLC和BCLC分类的预后准确性进行验证。

Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.

作者信息

Heinrich Sophia, Sprinzl Martin, Schmidtmann Irene, Heil Elena, Koch Sandra, Czauderna Carolin, Heinrich Bernd, Philippe P Diggs Laurence, Wörns Marcus-Alexander, Kloeckner Roman, Galle Peter R, Marquardt Jens U, Weinmann Arndt

机构信息

Department of Medicine I, University Medical Center, Mainz, Germany.

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.

出版信息

United European Gastroenterol J. 2020 May;8(4):444-452. doi: 10.1177/2050640620904524. Epub 2020 Jan 29.

DOI:10.1177/2050640620904524
PMID:32213028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7226688/
Abstract

BACKGROUND AND AIM

The Barcelona Clinic Liver Cancer (BCLC) staging system is commonly used to classify hepatocellular carcinoma (HCC) patients. However, other staging classification schemes have been proposed. We aimed to compare the prognostic accuracy of the Hong Kong Liver Cancer Staging (HKLC), the Model to Estimate Survival for HCC (MESH), and the BCLC staging systems using a Western cohort of HCC patients.

METHODS

We retrospectively analyzed 918 patients diagnosed with HCC treated at the University Medical Center of Mainz between 2005 and 2014. We compared the predictive power of survival time of the BCLC, HKLC, and MESH. Predictive ability was tested using the integrated Brier score (IBS) and Harrell's C index.

RESULTS

Kaplan-Meier analyses showed significant differences in survival between stages defined by the BCLC, HKLC, and MESH. The HKLC classification demonstrated a more robust classification concordance and lower prediction error compared to the BCLC and MESH. In addition, we found that the BCLC offers superior predictive ability to the MESH in the first four years, whereas the MESH is superior for long-term predictions.

CONCLUSION

Our analyses confirm the prognostic value of three different HCC scoring systems. When compared, the HKLC provides superior prognostication ability.

摘要

背景与目的

巴塞罗那临床肝癌(BCLC)分期系统常用于对肝细胞癌(HCC)患者进行分类。然而,也有人提出了其他分期分类方案。我们旨在使用西方HCC患者队列比较香港肝癌分期(HKLC)、肝癌生存预估模型(MESH)和BCLC分期系统的预后准确性。

方法

我们回顾性分析了2005年至2014年间在美因茨大学医学中心接受治疗的918例诊断为HCC的患者。我们比较了BCLC、HKLC和MESH对生存时间的预测能力。使用综合Brier评分(IBS)和Harrell's C指数测试预测能力。

结果

Kaplan-Meier分析显示,BCLC、HKLC和MESH定义的分期之间在生存方面存在显著差异。与BCLC和MESH相比,HKLC分类表现出更强的分类一致性和更低的预测误差。此外,我们发现BCLC在前四年的预测能力优于MESH,而MESH在长期预测方面更具优势。

结论

我们的分析证实了三种不同HCC评分系统的预后价值。相比之下,HKLC具有更优的预后预测能力。

相似文献

1
Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.在德国一个大型肝细胞癌患者队列中对MESH、HKLC和BCLC分类的预后准确性进行验证。
United European Gastroenterol J. 2020 May;8(4):444-452. doi: 10.1177/2050640620904524. Epub 2020 Jan 29.
2
Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.巴塞罗那临床肝癌分期系统在多民族亚洲人中对肝细胞癌的分期表现优于香港肝癌分期系统:基于现实世界的视角
World J Gastroenterol. 2017 Jun 14;23(22):4054-4063. doi: 10.3748/wjg.v23.i22.4054.
3
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.香港肝癌分期系统的建立与肝癌患者治疗分层策略。
Gastroenterology. 2014 Jun;146(7):1691-700.e3. doi: 10.1053/j.gastro.2014.02.032. Epub 2014 Feb 25.
4
Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma.香港肝癌巴塞罗那临床肝癌分期系统在肝细胞癌中的预后性能。
BMC Gastroenterol. 2024 Sep 18;24(1):318. doi: 10.1186/s12876-024-03387-5.
5
Assessment of the Hong Kong Liver Cancer Staging System in Europe.香港肝癌分期系统在欧洲的评估。
Liver Int. 2016 Jun;36(6):911-7. doi: 10.1111/liv.13045. Epub 2016 Jan 21.
6
The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?BCLC 和 HKLC 分期系统的推荐治疗方案:遵循这些方案是否总能提高 HCC 患者的生存率?
Liver Int. 2016 Oct;36(10):1490-7. doi: 10.1111/liv.13107. Epub 2016 Mar 24.
7
Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.香港肝癌分期系统与肝细胞癌的更佳预后相关:特别强调病毒病因学。
Medicine (Baltimore). 2015 Oct;94(41):e1772. doi: 10.1097/MD.0000000000001772.
8
Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.肝细胞癌患者模型的验证:中国队列中香港肝癌分期系统与巴塞罗那临床肝癌分期系统的比较
Eur J Gastroenterol Hepatol. 2015 Oct;27(10):1180-6. doi: 10.1097/MEG.0000000000000418.
9
Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.巴塞罗那临床肝癌列线图及其他分期/评分系统在一组法国肝细胞癌患者中的应用
World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545.
10
Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.更积极的治疗能否改善肝细胞癌患者的预后?香港肝癌和巴塞罗那临床肝癌算法的直接比较。
Gut Liver. 2018 Jan 15;12(1):94-101. doi: 10.5009/gnl17040.

引用本文的文献

1
Is hepatic resection always a better choice than radiofrequency ablation for solitary hepatocellular carcinoma regardless of age and tumor size?对于单发肝细胞癌,无论年龄和肿瘤大小如何,肝切除术是否总是优于射频消融?
Biomol Biomed. 2023 Jul 3;23(4):705-717. doi: 10.17305/bb.2022.8507.
2
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications.肝细胞癌预后系统概述及ITA.LI.CA对MESH和CNLC分类的外部验证
Cancers (Basel). 2021 Apr 2;13(7):1673. doi: 10.3390/cancers13071673.
3
How to Treat Hepatocellular Carcinoma in Elderly Patients.如何治疗老年肝细胞癌患者
Pharmaceuticals (Basel). 2021 Mar 8;14(3):233. doi: 10.3390/ph14030233.
4
Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma.嘧啶合成中的关键酶CAD和CPS1可预测肝细胞癌的预后。
Cancers (Basel). 2021 Feb 11;13(4):744. doi: 10.3390/cancers13040744.
5
Predictive scores for hepatocellular carcinoma: a race with no winners?肝细胞癌的预测评分:一场没有赢家的竞赛?
Ann Transl Med. 2020 Oct;8(19):1211. doi: 10.21037/atm-20-3960.

本文引用的文献

1
Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update.亚太地区超出巴塞罗那临床肝癌治疗方案的伴门静脉癌栓肝细胞癌的手术切除:综述与更新
Oncotarget. 2017 Jun 27;8(54):93258-93278. doi: 10.18632/oncotarget.18735. eCollection 2017 Nov 3.
2
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).米兰标准(巴塞罗那临床肝癌扩展标准)以外肝癌患者的亲体肝移植的初步研究。
Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.
3
A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort.美国多中心队列中肝细胞癌分期系统的比较
Clin Gastroenterol Hepatol. 2018 May;16(5):781-782. doi: 10.1016/j.cgh.2017.10.001. Epub 2017 Oct 5.
4
Usefulness of the MESH score in a European hepatocellular carcinoma cohort.MESH评分在欧洲肝细胞癌队列中的效用。
World J Hepatol. 2017 May 28;9(15):711-714. doi: 10.4254/wjh.v9.i15.711.
5
Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.巴塞罗那临床肝癌列线图及其他分期/评分系统在一组法国肝细胞癌患者中的应用
World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545.
6
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.TACE 治疗后中晚期肿瘤:从手术到系统治疗。
J Hepatol. 2017 Jul;67(1):173-183. doi: 10.1016/j.jhep.2017.03.007. Epub 2017 Mar 18.
7
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
8
Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.香港肝癌分期系统在确定北美患者动脉内治疗后预后中的验证
Clin Gastroenterol Hepatol. 2017 May;15(5):746-755.e4. doi: 10.1016/j.cgh.2016.10.036. Epub 2016 Nov 12.
9
Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients.提出并验证了一种新的模型,用于估计肝癌患者的生存情况。
Eur J Cancer. 2016 Aug;63:25-33. doi: 10.1016/j.ejca.2016.04.023. Epub 2016 May 31.
10
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.《1975 - 2012年美国癌症现状年度报告》,重点关注肝癌发病率上升情况
Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9.